NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
NK105 is a micellar nanoparticle formulation designed to enhance the delivery of paclitaxel (PTX) to solid tumours. It has been reported to exert antitumour activity in vivo and to have reduced neurotoxicity as compared to that of free PTX. The purpose of this study was to investigate the radiosensitising effect of NK105 in comparison with that of PTX. Lewis lung carcinoma (LLC)-bearing mice were administered a single intravenous (i.v.) injection of PTX or NK105; 24 h after the drug administration, a proportion of the mice received radiation to the tumour site or lung fields. Then, the antitumour activity and lung toxicity were evaluated. In one subset of mice, the tumours were excised and specimens were prepared for analysis of the cell cycle distribution by flow cytometry. Combined NK105 treatment with radiation yielded significant superior antitumour activity as compared to combined PTX treatment with radiation (P=0.0277). On the other hand, a histopathological study of lung sections revealed no significant difference in histopathological changes between mice treated with PTX and radiation and those treated with NK105 and radiation. Flow-cytometric analysis showed that NK105-treated LLC tumour cells showed more severe arrest at the G2/M phase as compared to PTX-treated tumour cells. The superior radiosensitising activity of NK105 was thus considered to be attributable to the more severe cell cycle arrest at the G2/M phase induced by NK105 as compared to that induced by free PTX. The present study results suggest that further clinical trials are warranted to determine the efficacy and feasibility of combined NK105 therapy with radiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Self-citationUchino, H., Matsumura, Y., Negishi, T., Koizumi, F., Hayashi, T., Honda, T., Nishiyama, N., Kataoka, K., Naito, S., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602772 · Cited by 430 · cited 1×
“We demonstrated that the incorporation of cisplatin into micelles significantly reduced the nephrotoxicity and neurotoxicity of cisplatin (Uchino et al, 2005).”
BackgroundSelf-citation
Cited by
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Polymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
Kim, S., Shi, Y., Kim, J. Y., Park, K., & Cheng, J.-X. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903380446 · Cited by 549
Polymeric nanoparticles: the future of nanomedicine
Banik, B. L., Fattahi, P., & Brown, J. L. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1364 · Cited by 485
Gene therapy and DNA delivery systems
Ibraheem, D., Elaissari, A., & Fessi, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.11.041 · Cited by 454
Metadata
- Authors
- Negishi, T., Koizumi, F., Uchino, H., Kuroda, J., Kawaguchi, T., Naito, S., & Matsumura, Y.
- Venue
- British Journal of Cancer
- Published
- 2006-08-08
- Volume
- 95
- Issue
- 5
- Pages
- 601-606
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2067273312
- Cited by
- 92
- References
- 3
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. https://app.cochat.ai/papers/10.1038/sj.bjc.6603311
- The paper
- Negishi, T., Koizumi, F., Uchino, H., Kuroda, J., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006). NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.